Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

被引：0
|
作者：
Abou-Alfa, G. K. [1 ]
Borbath, I. [2 ]
Clarke, S. J. [3 ]
Hitre, E. [4 ]
Louvet, C. [5 ]
Macarulla, T. [6 ]
Oh, D-Y. [7 ]
Spratlin, J. L. [8 ]
Valle, J. W. [9 ]
Weiss, K. H. [10 ]
Berman, C. [11 ]
Howland, M. [12 ]
Ye, Y. [13 ]
Cho, T. [14 ]
Moran, S. [11 ]
Javle, M. M. [15 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Clin Univ St Luc Bruxelles, HepatoGastroenterol & Digest Oncol, Brussels, Belgium
[3] Univ Sydney, Med Oncol, Sydney, NSW, Australia
[4] Natl Inst Oncol, Med Oncol, Budapest, Hungary
[5] Inst Mutualiste Montsouris, Med Oncol, Paris, France
[6] Hosp Valle De Hebron, Med Oncol, Barcelona, Spain
[7] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea
[8] Alberta Hlth Serv, Med Oncol, Edmonton, AB, Canada
[9] Univ Manchester, Med Oncol, Christie, Manchester, Lancs, England
[10] Univ Hosp Heidelberg, Transplant Hepatol, Heidelberg, Germany
[11] QED Therapeut Inc, Clin Dev, San Francisco, CA USA
[12] QED Therapeut Inc, Clin Sci, San Francisco, CA USA
[13] QED Therapeut Inc, Biostat, San Francisco, CA USA
[14] QED Therapeut Inc, Clin Operat, San Francisco, CA USA
[15] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
832TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
    Javle, Milind M.
    Borbath, Ivan
    Clarke, Stephen John
    Hitre, Erika
    Louvet, Christophe
    Mercade, Teresa Macarulla
    Oh, Do-Youn
    Spratlin, Jennifer L.
    Valle, Juan W.
    Weiss, Karl Heinz
    Berman, Craig
    Howland, Michael
    Ye, Yining
    Cho, Terry
    Moran, Susan
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
    Javle, M.
    Borbath, I.
    Clarke, S.
    Hitre, E.
    Louver, C.
    Macarulla, T.
    Oh, D.
    Spratlin, J.
    Valee, J.
    Weiss, K.
    Berman, C.
    Howland, M.
    Ye, Y.
    Cho, T.
    Moran, S.
    Abou-Alfa, C.
    ANNALS OF ONCOLOGY, 2019, 30 : 62 - 62
  • [3] PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
    Abou-Alfa, G. K.
    Borbath, I.
    Cohn, A. L.
    Goyal, L.
    Lamarca, A.
    Macarulla, T.
    Oh, D-Y.
    Roychowdhury, S.
    Sadeghi, S.
    Shroff, R. T.
    Howland, M.
    Li, A.
    Cho, T.
    Pande, A.
    Javle, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S701 - S702
  • [4] PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
    Abou-Alfa, Ghassan K.
    Borbath, Ivan
    Goyal, Lipika
    Lamarca, Angela
    Macarulla, Teresa
    Oh, Do-Youn
    Roychowdhury, Sameek
    Sadeghi, Saeed
    Shroff, Rachna T.
    Li, Ai
    Soto, Jose
    Avogadri, Francesca
    Dambkowski, Carl L.
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
    Abou-Alfa, G.
    Borbath, I.
    Goyal, L.
    Lamarca, A.
    Macarulla, T.
    Oh, D.
    Roychowdhury, S.
    Sadeghi, S.
    Shroff, R.
    Soto, J.
    Pedrioli, G.
    Fumagalli, L.
    Dambkowski, C.
    Javle, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S251 - S252
  • [6] Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial
    Abou-Alfa, G.
    Borbath, I.
    Cohn, A.
    Goyal, L.
    Lamarca, A.
    Macarulla, T.
    Oh, D.
    Roychowdhury, S.
    Sadeghi, S.
    Shroff, R.
    Howland, M.
    Li, A.
    Cho, T.
    Pande, A.
    Javle, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S136 - S137
  • [7] Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
    Makawita, Shalini
    Abou-Alfa, Ghassan K.
    Roychowdhury, Sameek
    Sadeghi, Saeed
    Borbath, Ivan
    Goyal, Lipika
    Cohn, Allen
    Lamarca, Angela
    Oh, Do-Youn
    Macarulla, Teresa
    Shroff, Rachna T.
    Howland, Michael
    Li, Ai
    Cho, Terry
    Pande, Amit
    Javle, Milind
    FUTURE ONCOLOGY, 2020, 16 (30) : 2375 - 2384
  • [8] PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
    Abou-Alfa, Ghassan K.
    Borbath, Ivan
    Roychowdhury, Sameek
    Goyal, Lipika
    Lamarca, Angela
    Macarulla, Teresa
    Shroff, Rachna T.
    Oh, Do-Youn
    Javle, Milind M.
    Tamas, Catalin
    Savastano, David M.
    Van Veenhuyzen, David Friedrich
    Xu, Cindy
    Solanas, Jacki
    Freas, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 516 - 516
  • [9] Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
    Javle, Milind
    Roychowdhury, Sameek
    Kelley, Robin Kate
    Sadeghi, Saeed
    Macarulla, Teresa
    Weiss, Karl Heinz
    Waldschmidt, Dirk-Thomas
    Goyal, Lipika
    Borbath, Ivan
    El-Khoueiry, Anthony
    Borad, Mitesh J.
    Yong, Wei Peng
    Philip, Philip A.
    Bitzer, Michael
    Tanasanvimon, Surbpong
    Li, Ai
    Pande, Amit
    Soifer, Harris S.
    Shepherd, Stacie Peacock
    Moran, Susan
    Zhu, Andrew X.
    Bekaii-Saab, Tanios S.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 803 - 815
  • [10] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
    Goyal, Lipika
    Meric-Bernstam, Funda
    Hollebecque, Antoine
    Valle, Juan W.
    Morizane, Chigusa
    Karasic, Thomas Benjamin
    Furuse, Junji
    He, Yaohua
    Soni, Nital
    Benhadji, Karim A.
    Bridgewater, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345